SHIFT Newsroom · GLOBAL
Retatrutide outperformed Ozempic in diabetes trial; not yet approved
Lilly reported Phase 3 results on 28 October 2026.
In TRANSCEND-T2D-2, adults with type 2 diabetes taking retatrutide lost an average 19.5%–20.9% of body weight over 80 weeks, versus 9.4% with Ozempic 2 mg. HbA1c fell 2.2 percentage points versus 1.8.
Side effects matter too: 4.8%–7.9% stopped retatrutide because of adverse events, versus 2.7% with Ozempic. Digestive problems were common.
These are Lilly’s headline findings, using an analysis estimating outcomes if participants remained on treatment without additional glucose-lowering medication. Full peer-reviewed results are pending. This was not a comparison with Wegovy’s obesity regimen or Mounjaro.
SHIFT’s take
Promising research, not a treatment offer: retatrutide remains investigational and unapproved.
Known facts
- The trial studied adults with type 2 diabetes.